CMS Drug Coverage Could Be Driven By Commercial Plan Decisions Under Proposal
Executive Summary
Proposed rule would also clarify standard for determining whether coverage of a drug, device, or biologic is ‘reasonable and necessary.’
You may also be interested in...
Medicare Coverage Policy Change Opens Up Commercial Market Pathway – If Biden Likes It
Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.
Biogen’s Aducanumab And The Case For A Medicare-Driven Clinical Trial
Peter Bach warns against Medicare ceding its scientific authority to FDA and automatically covering all drugs and devices the agency clears, suggesting the Alzheimer’s drug be subject to a CMS Innovation Center trial if FDA-approved. Others say the drug could highlight flaws in Medicare Part B’s payment system.
Medicare Final CAR-T Policy Eases Coverage Requirements
Product developers and researchers applaud the changes, including dropping "coverage with evidence development" approach.